D
Dicerna Pharmaceuticals
Lexington, United States
Founded 2006
About
RNAi therapeutics using GalXC delivery platform for liver-targeted gene silencing
Company Details
- Type
- commercial
- Employees
- 200+
- Funding
- $600M+
- Parent Company
- Novo Nordisk
Key Products
- GalXC Platform
- Nedosiran